APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rare Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rare Disease Drug Market Outlook and Growth Opportunities 2026

Report ID 174030960420 December 2025214 pages

Choose your research edition.

Industry ResearchRare Disease Drug Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Disease Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Rare Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Disease Drug Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Disease Drug Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Rare Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rare Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rare Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rare Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rare Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rare Disease Drug market include Alexion Pharmaceuticals, Inc., Amgen, Inc., Atara Biotherapeutics, Bayer AG, Biogen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited and Deciphera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rare Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rare Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rare Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rare Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Rare Disease Drug Segment by Company

Alexion Pharmaceuticals, Inc.

Amgen, Inc.

Atara Biotherapeutics

Bayer AG

Biogen, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Daiichi Sankyo Company Limited

Deciphera

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Novo Nordisk A/S

ProQR

AstraZeneca

GlaxoSmithKline

Pfizer, Inc.

Eli Lilly and Company

Merck & Co., Inc.

Novartis AG

Johnson & Johnson

Sanofi S.A.

Takeda

Rare Disease Drug Segment by Type

Below 0.1‰

Above 1‰

0.65‰～1‰

Rare Disease Drug Segment by Application

Speciality Pharmacies

Hospital Pharmacies

Retail pharmacies

Others

Rare Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Rare Disease Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Rare Disease Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rare Disease Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Rare Disease Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rare Disease Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rare Disease Drug industry.

Chapter 3: Detailed analysis of Rare Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Rare Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Rare Disease Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rare Disease Drug Industry Trends Table 2. Rare Disease Drug Industry Drivers Table 3. Rare Disease Drug Industry Opportunities and Challenges Table 4. Rare Disease Drug Industry Restraints Table 5. Global Rare Disease Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rare Disease Drug Revenue Share by Company (2021-2026) Table 7. Global Rare Disease Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Rare Disease Drug Sales Volume Share by Company (2021-2026) Table 9. Global Rare Disease Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Rare Disease Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Rare Disease Drug Key Company Manufacturing Base & Headquarters Table 12. Global Rare Disease Drug Company, Product Type & Application Table 13. Global Rare Disease Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Rare Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Below 0.1‰ Table 18. Significant Companies of Above 1‰ Table 19. Significant Companies of 0.65‰～1‰ Table 20. Global Rare Disease Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Rare Disease Drug Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Rare Disease Drug Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Rare Disease Drug Sales Volume Share by Type (2021-2026) Table 24. Global Rare Disease Drug Sales Volume Share by Type (2027-2032) Table 25. Global Rare Disease Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Rare Disease Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Rare Disease Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Rare Disease Drug Sales Value Share by Type (2021-2026) Table 29. Global Rare Disease Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Speciality Pharmacies Table 31. Significant Companies of Hospital Pharmacies Table 32. Significant Companies of Retail pharmacies Table 33. Significant Companies of Others Table 34. Global Rare Disease Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Rare Disease Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Rare Disease Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Rare Disease Drug Sales Volume Share by Application (2021-2026) Table 38. Global Rare Disease Drug Sales Volume Share by Application (2027-2032) Table 39. Global Rare Disease Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Rare Disease Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Rare Disease Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Rare Disease Drug Sales Value Share by Application (2021-2026) Table 43. Global Rare Disease Drug Sales Value Share by Application (2027-2032) Table 44. Global Rare Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Rare Disease Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Rare Disease Drug Sales Market Share by Region (2021-2026) Table 47. Global Rare Disease Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Rare Disease Drug Sales Market Share by Region (2027-2032) Table 49. Global Rare Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Rare Disease Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Rare Disease Drug Sales Value Share by Region (2021-2026) Table 52. Global Rare Disease Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Rare Disease Drug Sales Value Share by Region (2027-2032) Table 54. Global Rare Disease Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Rare Disease Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Rare Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Rare Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 59. Global Rare Disease Drug Sales Market Share by Country (2021-2026) Table 60. Global Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Rare Disease Drug Sales Market Share by Country (2027-2032) Table 62. Global Rare Disease Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Rare Disease Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Rare Disease Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Rare Disease Drug Sales Value Market Share by Country (2027-2032) Table 66. Alexion Pharmaceuticals, Inc. Company Information Table 67. Alexion Pharmaceuticals, Inc. Business Overview Table 68. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio Table 70. Alexion Pharmaceuticals, Inc. Recent Development Table 71. Amgen, Inc. Company Information Table 72. Amgen, Inc. Business Overview Table 73. Amgen, Inc. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Amgen, Inc. Rare Disease Drug Product Portfolio Table 75. Amgen, Inc. Recent Development Table 76. Atara Biotherapeutics Company Information Table 77. Atara Biotherapeutics Business Overview Table 78. Atara Biotherapeutics Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Atara Biotherapeutics Rare Disease Drug Product Portfolio Table 80. Atara Biotherapeutics Recent Development Table 81. Bayer AG Company Information Table 82. Bayer AG Business Overview Table 83. Bayer AG Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Bayer AG Rare Disease Drug Product Portfolio Table 85. Bayer AG Recent Development Table 86. Biogen, Inc. Company Information Table 87. Biogen, Inc. Business Overview Table 88. Biogen, Inc. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Biogen, Inc. Rare Disease Drug Product Portfolio Table 90. Biogen, Inc. Recent Development Table 91. Bristol-Myers Squibb Company Company Information Table 92. Bristol-Myers Squibb Company Business Overview Table 93. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio Table 95. Bristol-Myers Squibb Company Recent Development Table 96. Celgene Corporation Company Information Table 97. Celgene Corporation Business Overview Table 98. Celgene Corporation Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Celgene Corporation Rare Disease Drug Product Portfolio Table 100. Celgene Corporation Recent Development Table 101. Daiichi Sankyo Company Limited Company Information Table 102. Daiichi Sankyo Company Limited Business Overview Table 103. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio Table 105. Daiichi Sankyo Company Limited Recent Development Table 106. Deciphera Company Information Table 107. Deciphera Business Overview Table 108. Deciphera Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Deciphera Rare Disease Drug Product Portfolio Table 110. Deciphera Recent Development Table 111. Eisai Co., Ltd. Company Information Table 112. Eisai Co., Ltd. Business Overview Table 113. Eisai Co., Ltd. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Eisai Co., Ltd. Rare Disease Drug Product Portfolio Table 115. Eisai Co., Ltd. Recent Development Table 116. F. Hoffmann-La Roche Ltd. Company Information Table 117. F. Hoffmann-La Roche Ltd. Business Overview Table 118. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio Table 120. F. Hoffmann-La Roche Ltd. Recent Development Table 121. Novo Nordisk A/S Company Information Table 122. Novo Nordisk A/S Business Overview Table 123. Novo Nordisk A/S Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Novo Nordisk A/S Rare Disease Drug Product Portfolio Table 125. Novo Nordisk A/S Recent Development Table 126. ProQR Company Information Table 127. ProQR Business Overview Table 128. ProQR Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. ProQR Rare Disease Drug Product Portfolio Table 130. ProQR Recent Development Table 131. AstraZeneca Company Information Table 132. AstraZeneca Business Overview Table 133. AstraZeneca Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. AstraZeneca Rare Disease Drug Product Portfolio Table 135. AstraZeneca Recent Development Table 136. GlaxoSmithKline Company Information Table 137. GlaxoSmithKline Business Overview Table 138. GlaxoSmithKline Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. GlaxoSmithKline Rare Disease Drug Product Portfolio Table 140. GlaxoSmithKline Recent Development Table 141. Pfizer, Inc. Company Information Table 142. Pfizer, Inc. Business Overview Table 143. Pfizer, Inc. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Pfizer, Inc. Rare Disease Drug Product Portfolio Table 145. Pfizer, Inc. Recent Development Table 146. Eli Lilly and Company Company Information Table 147. Eli Lilly and Company Business Overview Table 148. Eli Lilly and Company Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Eli Lilly and Company Rare Disease Drug Product Portfolio Table 150. Eli Lilly and Company Recent Development Table 151. Merck & Co., Inc. Company Information Table 152. Merck & Co., Inc. Business Overview Table 153. Merck & Co., Inc. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Merck & Co., Inc. Rare Disease Drug Product Portfolio Table 155. Merck & Co., Inc. Recent Development Table 156. Novartis AG Company Information Table 157. Novartis AG Business Overview Table 158. Novartis AG Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Novartis AG Rare Disease Drug Product Portfolio Table 160. Novartis AG Recent Development Table 161. Johnson & Johnson Company Information Table 162. Johnson & Johnson Business Overview Table 163. Johnson & Johnson Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Johnson & Johnson Rare Disease Drug Product Portfolio Table 165. Johnson & Johnson Recent Development Table 166. Sanofi S.A. Company Information Table 167. Sanofi S.A. Business Overview Table 168. Sanofi S.A. Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Sanofi S.A. Rare Disease Drug Product Portfolio Table 170. Sanofi S.A. Recent Development Table 171. Takeda Company Information Table 172. Takeda Business Overview Table 173. Takeda Rare Disease Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Takeda Rare Disease Drug Product Portfolio Table 175. Takeda Recent Development Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Rare Disease Drug Distributors List Table 179. Rare Disease Drug Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Rare Disease Drug Product Image Figure 2. Global Rare Disease Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rare Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Rare Disease Drug Sales (2021-2032) & (K Units) Figure 5. Global Rare Disease Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Rare Disease Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Below 0.1‰ Image Figure 10. Above 1‰ Image Figure 11. 0.65‰～1‰ Image Figure 12. Global Rare Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Rare Disease Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Rare Disease Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Rare Disease Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Rare Disease Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Rare Disease Drug Sales Value Share by Type (2021-2032) Figure 18. Speciality Pharmacies Image Figure 19. Hospital Pharmacies Image Figure 20. Retail pharmacies Image Figure 21. Others Image Figure 22. Global Rare Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Rare Disease Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Rare Disease Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Rare Disease Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Rare Disease Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Rare Disease Drug Sales Value Share by Application (2021-2032) Figure 28. Global Rare Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Rare Disease Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Rare Disease Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Rare Disease Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Rare Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Rare Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Rare Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Rare Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Rare Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Rare Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Rare Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Rare Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Rare Disease Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Rare Disease Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Rare Disease Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Rare Disease Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Rare Disease Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Rare Disease Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Rare Disease Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Below 0.1‰
  • Above 1‰
  • 0.65‰～1‰
Applications
  • Speciality Pharmacies
  • Hospital Pharmacies
  • Retail pharmacies
  • Others
Companies covered
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • Atara Biotherapeutics
  • Bayer AG
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company Limited
  • Deciphera
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • ProQR
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Rare Disease Drug Sales Value (2021-2032)
  4. 1.2.2 Global Rare Disease Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Rare Disease Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Rare Disease Drug Market Dynamics
  1. 2.1 Rare Disease Drug Industry Trends
  2. 2.2 Rare Disease Drug Industry Drivers
  3. 2.3 Rare Disease Drug Industry Opportunities and Challenges
  4. 2.4 Rare Disease Drug Industry Restraints
3 Rare Disease Drug Market by Company
  1. 3.1 Global Rare Disease Drug Company Revenue Ranking in 2025
  2. 3.2 Global Rare Disease Drug Revenue by Company (2021-2026)
  3. 3.3 Global Rare Disease Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Rare Disease Drug Average Price by Company (2021-2026)
  5. 3.5 Global Rare Disease Drug Company Ranking (2024-2026)
  6. 3.6 Global Rare Disease Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Rare Disease Drug Company Product Type and Application
  8. 3.8 Global Rare Disease Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Rare Disease Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Rare Disease Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Rare Disease Drug Market by Type
  1. 4.1 Rare Disease Drug Type Introduction
  2. 4.1.1 Below 0.1‰
  3. 4.1.2 Above 1‰
  4. 4.1.3 0.65‰～1‰
  5. 4.2 Global Rare Disease Drug Sales Volume by Type
  6. 4.2.1 Global Rare Disease Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Rare Disease Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Rare Disease Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Rare Disease Drug Sales Value by Type
  10. 4.3.1 Global Rare Disease Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Rare Disease Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Rare Disease Drug Sales Value Share by Type (2021-2032)
5 Rare Disease Drug Market by Application
  1. 5.1 Rare Disease Drug Application Introduction
  2. 5.1.1 Speciality Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail pharmacies
  5. 5.1.4 Others
  6. 5.2 Global Rare Disease Drug Sales Volume by Application
  7. 5.2.1 Global Rare Disease Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Rare Disease Drug Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Rare Disease Drug Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Rare Disease Drug Sales Value by Application
  11. 5.3.1 Global Rare Disease Drug Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Rare Disease Drug Sales Value by Application (2021-2032)
  13. 5.3.3 Global Rare Disease Drug Sales Value Share by Application (2021-2032)
6 Rare Disease Drug Regional Sales and Value Analysis
  1. 6.1 Global Rare Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rare Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Rare Disease Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Rare Disease Drug Sales by Region (2027-2032)
  5. 6.3 Global Rare Disease Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Rare Disease Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Rare Disease Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Rare Disease Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Rare Disease Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Rare Disease Drug Sales Value (2021-2032)
  12. 6.6.2 North America Rare Disease Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Rare Disease Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Rare Disease Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Rare Disease Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Rare Disease Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Rare Disease Drug Sales Value (2021-2032)
  21. 6.9.2 South America Rare Disease Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Rare Disease Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Rare Disease Drug Sales Value Share by Country, 2025 VS 2032
7 Rare Disease Drug Country-level Sales and Value Analysis
  1. 7.1 Global Rare Disease Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rare Disease Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Rare Disease Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Rare Disease Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Rare Disease Drug Sales by Country (2027-2032)
  6. 7.4 Global Rare Disease Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Rare Disease Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Rare Disease Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Rare Disease Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Rare Disease Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Rare Disease Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Rare Disease Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Rare Disease Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Rare Disease Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Rare Disease Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Rare Disease Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Rare Disease Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Rare Disease Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Rare Disease Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Rare Disease Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Rare Disease Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Rare Disease Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Rare Disease Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Rare Disease Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Rare Disease Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Rare Disease Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Rare Disease Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Rare Disease Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Rare Disease Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Rare Disease Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Rare Disease Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Rare Disease Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Rare Disease Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Rare Disease Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Rare Disease Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Rare Disease Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Rare Disease Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Rare Disease Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals, Inc.
  2. 8.1.1 Alexion Pharmaceuticals, Inc. Company Information
  3. 8.1.2 Alexion Pharmaceuticals, Inc. Business Overview
  4. 8.1.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals, Inc. Recent Developments
  7. 8.2 Amgen, Inc.
  8. 8.2.1 Amgen, Inc. Company Information
  9. 8.2.2 Amgen, Inc. Business Overview
  10. 8.2.3 Amgen, Inc. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen, Inc. Rare Disease Drug Product Portfolio
  12. 8.2.5 Amgen, Inc. Recent Developments
  13. 8.3 Atara Biotherapeutics
  14. 8.3.1 Atara Biotherapeutics Company Information
  15. 8.3.2 Atara Biotherapeutics Business Overview
  16. 8.3.3 Atara Biotherapeutics Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Atara Biotherapeutics Rare Disease Drug Product Portfolio
  18. 8.3.5 Atara Biotherapeutics Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Rare Disease Drug Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 Biogen, Inc.
  26. 8.5.1 Biogen, Inc. Company Information
  27. 8.5.2 Biogen, Inc. Business Overview
  28. 8.5.3 Biogen, Inc. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Biogen, Inc. Rare Disease Drug Product Portfolio
  30. 8.5.5 Biogen, Inc. Recent Developments
  31. 8.6 Bristol-Myers Squibb Company
  32. 8.6.1 Bristol-Myers Squibb Company Company Information
  33. 8.6.2 Bristol-Myers Squibb Company Business Overview
  34. 8.6.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 8.7 Celgene Corporation
  38. 8.7.1 Celgene Corporation Company Information
  39. 8.7.2 Celgene Corporation Business Overview
  40. 8.7.3 Celgene Corporation Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Celgene Corporation Rare Disease Drug Product Portfolio
  42. 8.7.5 Celgene Corporation Recent Developments
  43. 8.8 Daiichi Sankyo Company Limited
  44. 8.8.1 Daiichi Sankyo Company Limited Company Information
  45. 8.8.2 Daiichi Sankyo Company Limited Business Overview
  46. 8.8.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio
  48. 8.8.5 Daiichi Sankyo Company Limited Recent Developments
  49. 8.9 Deciphera
  50. 8.9.1 Deciphera Company Information
  51. 8.9.2 Deciphera Business Overview
  52. 8.9.3 Deciphera Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Deciphera Rare Disease Drug Product Portfolio
  54. 8.9.5 Deciphera Recent Developments
  55. 8.10 Eisai Co., Ltd.
  56. 8.10.1 Eisai Co., Ltd. Company Information
  57. 8.10.2 Eisai Co., Ltd. Business Overview
  58. 8.10.3 Eisai Co., Ltd. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eisai Co., Ltd. Rare Disease Drug Product Portfolio
  60. 8.10.5 Eisai Co., Ltd. Recent Developments
  61. 8.11 F. Hoffmann-La Roche Ltd.
  62. 8.11.1 F. Hoffmann-La Roche Ltd. Company Information
  63. 8.11.2 F. Hoffmann-La Roche Ltd. Business Overview
  64. 8.11.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio
  66. 8.11.5 F. Hoffmann-La Roche Ltd. Recent Developments
  67. 8.12 Novo Nordisk A/S
  68. 8.12.1 Novo Nordisk A/S Company Information
  69. 8.12.2 Novo Nordisk A/S Business Overview
  70. 8.12.3 Novo Nordisk A/S Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Novo Nordisk A/S Rare Disease Drug Product Portfolio
  72. 8.12.5 Novo Nordisk A/S Recent Developments
  73. 8.13 ProQR
  74. 8.13.1 ProQR Company Information
  75. 8.13.2 ProQR Business Overview
  76. 8.13.3 ProQR Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 ProQR Rare Disease Drug Product Portfolio
  78. 8.13.5 ProQR Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Rare Disease Drug Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 GlaxoSmithKline
  86. 8.15.1 GlaxoSmithKline Company Information
  87. 8.15.2 GlaxoSmithKline Business Overview
  88. 8.15.3 GlaxoSmithKline Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 GlaxoSmithKline Rare Disease Drug Product Portfolio
  90. 8.15.5 GlaxoSmithKline Recent Developments
  91. 8.16 Pfizer, Inc.
  92. 8.16.1 Pfizer, Inc. Company Information
  93. 8.16.2 Pfizer, Inc. Business Overview
  94. 8.16.3 Pfizer, Inc. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Pfizer, Inc. Rare Disease Drug Product Portfolio
  96. 8.16.5 Pfizer, Inc. Recent Developments
  97. 8.17 Eli Lilly and Company
  98. 8.17.1 Eli Lilly and Company Company Information
  99. 8.17.2 Eli Lilly and Company Business Overview
  100. 8.17.3 Eli Lilly and Company Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Eli Lilly and Company Rare Disease Drug Product Portfolio
  102. 8.17.5 Eli Lilly and Company Recent Developments
  103. 8.18 Merck & Co., Inc.
  104. 8.18.1 Merck & Co., Inc. Company Information
  105. 8.18.2 Merck & Co., Inc. Business Overview
  106. 8.18.3 Merck & Co., Inc. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Merck & Co., Inc. Rare Disease Drug Product Portfolio
  108. 8.18.5 Merck & Co., Inc. Recent Developments
  109. 8.19 Novartis AG
  110. 8.19.1 Novartis AG Company Information
  111. 8.19.2 Novartis AG Business Overview
  112. 8.19.3 Novartis AG Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Novartis AG Rare Disease Drug Product Portfolio
  114. 8.19.5 Novartis AG Recent Developments
  115. 8.20 Johnson & Johnson
  116. 8.20.1 Johnson & Johnson Company Information
  117. 8.20.2 Johnson & Johnson Business Overview
  118. 8.20.3 Johnson & Johnson Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Johnson & Johnson Rare Disease Drug Product Portfolio
  120. 8.20.5 Johnson & Johnson Recent Developments
  121. 8.21 Sanofi S.A.
  122. 8.21.1 Sanofi S.A. Company Information
  123. 8.21.2 Sanofi S.A. Business Overview
  124. 8.21.3 Sanofi S.A. Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Sanofi S.A. Rare Disease Drug Product Portfolio
  126. 8.21.5 Sanofi S.A. Recent Developments
  127. 8.22 Takeda
  128. 8.22.1 Takeda Company Information
  129. 8.22.2 Takeda Business Overview
  130. 8.22.3 Takeda Rare Disease Drug Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Takeda Rare Disease Drug Product Portfolio
  132. 8.22.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rare Disease Drug Value Chain Analysis
  2. 9.1.1 Rare Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rare Disease Drug Sales Mode & Process
  6. 9.2 Rare Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rare Disease Drug Distributors
  9. 9.2.3 Rare Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst